NOVUS Life Sciences Limited, founded in 2014 and headquartered in Hong Kong, is a global leader in 3D printing biomaterials. With advanced manufacturing facilities in Hong Kong and Shenzhen, we specialize in developing innovative materials for medical-grade 3D printing applications, particularly patient-specific implants and devices.
Our flagship product, Bonlecule filament, revolutionizes bone graft printing by enabling seamless integration with the patient's existing bone structure. We proudly supply to over 35 countries and 65 corporate clients, including top-tier institutions like the University of Oxford and National University Hospital in Singapore.
Under the visionary leadership of our Chairman and CEO, Dr. Wilson Wong, NOVUS has achieved over 100 clinical cases and sustained a remarkable 100%+ quarter growth in revenue. Our commitment to deep technology in biomaterials, rigorous quality standards, and comprehensive customer support positions us as a critical element in the global medical device supply chain.
NOVUS actively engages in the startup ecosystem and entrepreneurship education, consistently receiving prestigious awards such as Champion of IMAGINE IF!, CNBC’s hottest startups, and accolades from Hong Kong Business Magazine, GIN Austria, French Tech Ticket, and Alibaba Jumpstarter.
Join us in transforming healthcare with cutting-edge 3D printing technology and innovative biomaterials.
#MedicalInnovation #3DPrinting #Biomaterials #HealthcareRevolution #NOVUSLifeSciences
-
Industry
-
Biotechnology
-
Company size
-
11-50 employees
-
Headquarters
-
Sha Tin District
-
Type
-
Privately Held
-
Founded
-
2014
-
Specialties
-
Biotechnology, Research and Development, Medical 3D Printing, Medical Devices, 3D Printing, Implants, Veterinary Devices, and Biomaterials